



ATTORNEYS. AT LAW



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbal
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger
Judith U. Kim
Timothy J. Shea, Jr.

Patrick E. Garrett
Jeffery T. Helvey*
Heidi L. Kraus
Crystal D. Sayles
Edward W. Yee
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Albert J. Fasulo II*
Eldora Ellison Floyd
W. Russell Swindell
Thomas C. Fiala
Brian J. Del Buono*
Virgil Lee Beaston*
Reginald D. Lucas*

Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cotttingham*
Christine M. Luhauer
Rae Lynn Prengaman*
Jane Shershenovich*
Lawrence J. Carroll*
George S. Bardmessner

Senior Counsel
Samuel L. Fox
Kenneth C. Bass III

Registered Patent Agents
Karen R. Markowicz
Andrea J. Kamage

Nancy J. Leith
Joseph M. Conrad III
Ann E. Summerfield
Helene C. Carlson
Gaby L. Longsworth
Matthew J. Dowd
Aaron L. Schwartz
Angelique G. Uy
Boris A. Matvenko
Mary B. Tung
Katrina Y. Pei
Bryan L. Skelton
Jason D. Eisenberg

*Admitted only in Maryland
*Admitted only in Virginia
*Admitted only in Texas

1647
TECH CENTER 1600/2900
JUN 04 2002
RECEIVED

May 31, 2002

WRITER'S DIRECT NUMBER:
(202) 371-2637

INTERNET ADDRESS:
KAREN.M@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Art Unit 1647

Re: U.S. Utility Patent Application
Appl. No. 09/712,142; Filed: November 15, 2000
For: **Connective Tissue Growth Factor-3**
Inventors: Ebner *et al.*
Our Ref: 1488.0630002/EKS/KRM

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Second Supplemental Information Disclosure Statement;
2. Listing of the cited documents on Form PTO-1449 (1 sheet);
3. A copy of each of the two (2) cited documents on Form PTO-1449; and
4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
May 31, 2002
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

KRM/pcd
Enclosures

SKGF_DC1:19745.1

RECEIVED

JUN 04 2002

15
er
65
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

O 1.5
1 MAY 3 1 2002
SEARCHED
INDEXED
MAILED
PCT
In re application of:

Ebner *et al.*

Appl. No. 09/712,142

Filed: November 15, 2000

For: **Connective Tissue Growth Factor-3**

Art Unit: 1647

Examiner: *To be assigned*

Atty. Docket: 1488.0630002/EKS/KRM

Second Supplemental Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Information Disclosure Statement filed on March 29, 2002 in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to SEQ ID NOS:1762, 73132, and 196475 in copending U.S. Patent Application Serial No. 09/912,293, and to SEQ ID NO:46156 in copending U.S. Patent Application Serial No. 09/912,292. Further, SEQ ID NO:10 of this application is related to SEQ ID NO:196475 in copending U.S. Patent

Application Serial No. 09/912,293, and SEQ ID NO:11 of this application is related to SEQ ID NO:46156 in copending U.S. Patent Application Serial No. 09/912,292. Legible copies of those portions of U.S. Patent Application Serial Nos. 09/912,292 and 09/912,293 which caused them to be listed on the attached PTO-1449 are submitted herewith as references AS13 and AT13, respectively.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

Date: 5/31/02

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600